Comparison between DP2 antagonist and inhaled corticosteroid in the treatment of airway inflammation in bronchial asthma mice model G

Yi ONG,Liang DONG,Ning ZHU,Yuan-yuan ZHANG,Jing-wen XIA,Xiao-dong CHEN
DOI: https://doi.org/10.3969/j.issn.1009-6663.2015.05.020
2015-01-01
Abstract:Objective To understand the changes of airway inflammation by DP2 atagonist and to compare the differences between the DP2 antagonist and inhaled corticosteroid. Methods 24 male mice were randomly divid-ed into the normal control group, the asthma group, the DP2 antagonist group and the inhaled corticosteroid group ( n=6 for each group) . Asthma was induced by ovalbumin challenge. The levels of PGD2 , DP2 , IL-4 and IL-5 in bronchoalveolar lavage fluid were measured by ELISA. PGD2 and DP2 mRNA were tested by real-time PCR. Re-sults Compared with the normal control group, the asthma group had significant infiltration of inflammation cells in bronchial wall, which was the typical changes of asthma. The level of PGD2 , DP2 , IL-4 and IL-5 in BALF in the asthma group was significantly higher than that in the normal control group ( P<0. 01 ) . Both in the DP2 atagonist group and the inhaled corticosteroids group, the airway inflammation was inhibited compared with the asthma group. Conclusion DP2 antagonist can inhabit the inflammation of asthma in mice. DP2 antagonist probably can be the new drug of asthma like inhaled corticosteroid.
What problem does this paper attempt to address?